FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers ...

Cutaneous squamous-cell carcinoma (SCC) is primarily caused by oncogenesis mediated by ultraviolet radiation, and β-human papillomavirus (β-HPV) is believed to be a mere facilitator that is ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--NextPoint Therapeutics, a clinical-stage biotechnology company launching a new world of precision therapeutics through its leading scientific work on the novel B7-H7 ...

The past decade in oncology has been marked by the rise of immunotherapy, which leverages the immune system to attack tumors. For many solid tumors, immune checkpoint inhibitors have supplanted ...